Ribbon Communications Inc. (RBBN) earnings date, results and what the price requires
Nasdaq · SEC CIK 0001708055 · SEC filings checked Oct 18, 2026
Previous results (SEC filings)
| Quarter ended | Reported | Revenue | Net income | Diluted EPS | Source |
|---|---|---|---|---|---|
| Jun 30, 2026 | Jul 28, 2026 | $192.3M | $-26.9M | $-0.15 | Filing |
| Mar 31, 2026 | Apr 28, 2026 | $162.6M | $-34.5M | $-0.20 | Filing |
| Dec 31, 2025 | Feb 5, 2026 | $227.3M | $49.5M | $0.50 | Filing |
| Sep 30, 2025 | Oct 22, 2025 | $215.4M | $-12.1M | $-0.07 | Filing |
| Jun 30, 2025 | Jul 23, 2025 | $220.6M | $-11.1M | $-0.06 | Filing |
| Mar 31, 2025 | Apr 29, 2025 | $181.3M | $-26.2M | $-0.15 | Filing |
| Dec 31, 2024 | Feb 12, 2025 | $251.4M | $60.5M | $0.05 | Filing |
| Sep 30, 2024 | Oct 23, 2024 | $210.2M | $-13.4M | $-0.08 | Filing |
What would Ribbon Communications Inc. have to report for its valuation to change?
At $1.32, with a 9.0% required return and a 18× earnings multiple in 5 years, earnings per share must grow about 7.1% a year, to $0.11. On that path the next quarter needs diluted EPS near $-0.07, against $-0.07 in the quarter ended Sep 30, 2025.
Compare buying at the last close now with waiting for results: if the report moves the growth the price requires, the entry price you would accept changes with it.
| Result | Original | Yours |
|---|---|---|
| Required EPS growth / year | 7.1% | 7.1% |
| EPS needed in final year | $0.11 | $0.11 |
Changed: nothing yet. Model: EPS × (1+g)^years × final P/E, discounted at the required return, equals today's price. Inputs: SEC diluted EPS and the dated close above.
Prepare for earnings across my investments — $399/month
Keep working models for the companies you follow, compare your expectations with reported results, and review what changes your investment decision. RBBN goes in with your buy-or-wait comparison and assumptions preserved.
Figures come from SEC EDGAR XBRL filings. Dates marked "estimated" are calculated from the company's past results filings and are not confirmed. Not investment advice.